Your browser doesn't support javascript.
loading
Comparable humoral and cellular immunity against Omicron variant BA.4/5 of once-boosted BA.1/2 convalescents and twice-boosted COVID-19-naïve individuals.
Kang, Chang Kyung; Kim, Min-Gang; Park, Seong-Wook; Kim, Yong-Woo; Lee, Chan Mi; Choe, Pyoeng Gyun; Park, Wan Beom; Kim, Nam Joong; Kim, Minji; Lee, Soojin; Kim, Ik Soo; Lee, Chang-Han; Shin, Hyun Mu; Kim, Hang-Rae; Oh, Myoung-Don.
Afiliación
  • Kang CK; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Kim MG; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Park SW; Department of Anatomy & Cell Biology, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Kim YW; BK21 FOUR Biomedical Science Project, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Lee CM; Department of Pharmacology, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Choe PG; Wide River Institute of Immunology, Seoul National University, Hongcheon, Republic of Korea.
  • Park WB; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Kim NJ; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Kim M; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Lee S; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Kim IS; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Lee CH; Department of Anatomy & Cell Biology, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Shin HM; BK21 FOUR Biomedical Science Project, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Kim HR; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Oh MD; Department of Anatomy & Cell Biology, Seoul National University College of Medicine, Seoul, Republic of Korea.
J Med Virol ; 95(2): e28558, 2023 02.
Article en En | MEDLINE | ID: mdl-36755360
The fourth vaccination dose confers additional protective immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in individuals with no prior coronavirus disease-19 (COVID-19). However, its immunological benefit against currently circulating BA.4/5 is unclear in individuals who have received a booster shot and been infected with Omicron variant BA.1/2. We analyzed immune responses in whom had been boosted once and did not have COVID-19 (n = 16), boosted once and had COVID-19 when BA.1/2 was dominant in Korea (Hybrid-6M group, n = 27), and boosted twice and did not have COVID-19 (Vx4 group, n = 15). Antibody binding activities against RBDo BA.1 and RBDo BA.4/5 , antigen-specific memory CD4+ and CD8+ T-cell responses against BA.4/5, and B-cell responses against SARS-CoV-2 wild-type did not differ statistically between the Hybrid-6M and Vx4 groups. The humoral and cellular immune responses of the Hybrid-6M group against BA.4/5 were comparable to those of the Vx4 group. Individuals who had been boosted and had an Omicron infection in early 2022 may not have high priority for an additional vaccination.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans Idioma: En Revista: J Med Virol Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans Idioma: En Revista: J Med Virol Año: 2023 Tipo del documento: Article